Abstract
The class of antimetabolite chemotherapeutical agents has been used to treat cancers in humans for almost 50 years and gives significant results by binding dihydrofolate reductase (DHFR), a key enzyme in DNA synthesis. Therefore, finding new active compounds inhibiting DNA synthesis through their binding to DHFR is of prime interest. The aim of this work is to describe a protocol designed to study the binding of compounds to DHFR. This screening protocol involves matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) detection of target-bound compounds. Firstly, a screening protocol is developed and proves to be a simple, fast, and specific method to characterize the binding capability of a compound. Secondly, the possibility of determining the relative affinities of DHFR-binding compounds by comparing MALDI-TOFMS data is discussed. A ratio is calculated for a compound X such as \(R{\left( X \right)} = \frac{{A.I._{{denaturation}} {\left( X \right)}}}{{A.I._{{direct}} {\left( X \right)}}}\) (where AIdirect and AIdenaturation are the average absolute intensities of a binding compound X before and after denaturation of DHFR). It is shown that by using this protocol, one can characterize the strength of the binding of different compounds. These two strategies are then applied to screen green tea (Camellia sinensis) extracts for DHFR-binding compounds, and epigallocatechin gallate is shown to be an active compound with a relative affinity between those of pyrimethamine and methotrexate.
Similar content being viewed by others
References
Boyle P, Ferlay J (2005) Ann Oncol 16:481
Hannun YA (1997) Blood 89:1945
Kaye SB (1998) Br J Cancer 78:1
Schweitzer BI, Dicker AP, Bertino JR (1990) FASEB J 4:2441
Matthews DA, Bolin JT, Burridge JM, Filman DJ, Volz KW, Kraut J (1985) J Biol Chem 260:392
Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) N Engl J Med 309:1094
Vangapandu S, Jain M, Kaur K, Patil P, Patel SR, Jain R (2007) Med Res Rev 27:65
Widemann BC, Balis FM, Adamson PC (1999) Clin Chem 45:223
Brown LF, Johnson GF, Witte DL, Feld RD (1980) Clin Chem 26:335
McCullough JL, Weinstein GD, Hynes JB (1977) J Invest Dermatol 68:362
Nikolic D, v Breemen RB (1998) Comb Chem High Thoughput Screen 1:47
Johnson BM, Nikolic D, v Breemen RB (2002) Mass Spectrom Rev 21:76
Hannewald P, Maunit B, Muller JF (2006) Anal Chem 78:4390
Speicher A, Hollemeyer K, Heinzle E (2001) Rapid Commun Mass Spectrom 15:124
Rajaian H, Symonds HW, Bowmer CJ (1997) J Vet Pharmacol Ther 20:421
Vicken R, Vorperian MD, Thomas C, Miller S, Craig T (1997) J Am Coll Cardiol 30:791
ISO (1993) Guide to the expression of uncertainty in measurements. ISO, Geneva
Yang CS, Lambert JD, Hou Z, Ju J, Lu G, Hao X (2006) Mol Carcinogen 45:431
Mukhtar H, Ahmad N (2000) Am J Clin Nutr 71:1698
Navarro-Peran E, Cabezas-Herrera J, Garcia-Canovas F, Durrant MC, Thorneley RNF, Rodriguez-Lopez JN (2005) Cancer Res 65:2059
Mukhtar H, Ahmad N (1999) Toxicol Sci 52:111
Miketova P, Schram KH, Whitney JL, Kerns EH, Valvic S, Timmermann BN, Volk KJ (1998) J Nat Prod 61:461
Zeeb DJ, Nelson BC, Albert K, Dalluge JJ (2000) Anal Chem 72:5020
Kerwin JL (1996) J Mass Spectrom 31:1429
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hannewald, P., Maunit, B. & Muller, JF. Screening of DHFR-binding drugs by MALDI-TOFMS. Anal Bioanal Chem 392, 1335–1344 (2008). https://doi.org/10.1007/s00216-008-2409-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-008-2409-x